日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study

美国婴儿呼吸道合胞病毒下呼吸道疾病中,Nirsevimab 和 Clesrovimab 的成本效益分析:一项建模研究

Yarnoff, Benjamin; Beuvelet, Matthieu; Soudani, Samira; Neary, Maureen P; Hodges, Erin N; Chit, Ayman; Tribaldos, Maribel; Gabriel, Veronica; Musci, Robert; Geurtsen, Jeroen; Krilov, Leonard R

Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy

意大利呼吸道合胞病毒相关的经济和临床负担以及普遍接种尼塞维单抗的影响

Marcellusi, Andrea; Bini, Chiara; Muzii, Barbara; Soudani, Samira; Kieffer, Alexia; Beuvelet, Matthieu; Bozzola, Elena; Midulla, Fabio; Baraldi, Eugenio; Bonanni, Paolo; Boccalini, Sara; Orfeo, Luigi

Disease Burden Associated with All Infants in Their First RSV Season in the UK: A Static Model of Universal Immunization with Nirsevimab Against RSV-Related Outcomes

英国所有婴儿在首个呼吸道合胞病毒(RSV)流行季期间的疾病负担:使用尼塞维单抗进行普遍免疫接种以预防RSV相关疾病的静态模型

Kieffer, Alexia; Beuvelet, Matthieu; Moncayo, Gerald; Chetty, Mersha; Sardesai, Aditya; Musci, Robert; Hudson, Richard

Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain

对西班牙首次呼吸道合胞病毒季节中所有新生儿和婴儿进行全面免疫接种的潜在临床和经济影响进行建模,并与保护所有新生儿和婴儿的标准做法进行比较

Ruth Gil-Prieto, Jaime Jesus Pérez, Georgina Drago, Alexia Kieffer, Julie Roïz, Paulina Kazmierska, Aditya Sardesai, Solène de Boisvilliers, Juan Luis López-Belmonte, Matthieu Beuvelet, Javier Alvarez Aldean